NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
23 Aug 2012

TiGenix Business Update & Financial Highlights for the First Half of 2012

Leuven (BELGIUM) - August 23, 2012 -TiGenix NV (NYSE Euronext: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the half year ending June 30, 2012.
08 Aug 2012

TiGenix completes patient enrollment in Phase IIa rheumatoid arthritis study

Leuven (BELGIUM), Madrid (SPAIN) – August 8, 2012 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company’s Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis.
17 Jul 2012

TiGenix signs up 4th major hospital in the Netherlands for innovative cartilage repair therapy

Leuven (BELGIUM) – July 17, 2012 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today that after obtaining national reimbursement for ChondroCelect in the Netherlands last month, the company has now contracted with four major hospitals to make its innovative cartilage repair therapy available to their patients on a routine basis: University Medical Center Utrecht, University Hospital Maastricht, Martini Hospital Groningen, and, most recently, the Elisabeth Hospital Tilburg.
10 Jul 2012

TiGenix enrolls first patients in pivotal Phase III trial with lead product Cx601 in perianal fistulas

Leuven (BELGIUM) – July 10, 2012 – TiGenix (NYSE Euronext: TIG) announced today theenrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn´s disease patients at Hospital Clínic, Barcelona, Spain.
02 Jul 2012

TiGenix reports positive results of Cx621 Phase I

Leuven (BELGIUM) – July 2, 2012 – TiGenix (NYSE Euronext: TIG) announced today that it has successfully completed the company’s Phase I clinical trial to assess the safety of intra-lymphatic administration of its expanded adipose stem cells product (Cx621).
Ysios Capital leads a € 2M Series A round of Inbiomotion<
28 Jun 2012

Ysios Capital leads a € 2M Series A round of Inbiomotion

The proceeds of the financing will be used to continue the validation of its proprietary biomarker in a number of clinical studies and advance its development.
28 Jun 2012

Ysios Capital leads a € 2M Series A round of Inbiomotion

Barcelona June 28, 2012 –Ysios Capital, a leading Spanish life sciences venture capital firm, today announces that it has led the €2 million Series A financing of Inbiomotion SL, a spin-out company from the Growth Control and Cancer Metastasis group at the Institute for Research in Biomedicine (IRB Barcelona) and ICREA focused on the development of biomarkers for the prediction of bone metastasis from primary tumor biopsies.
13 Jun 2012

Endosense completes enrollment in toccastar ide study of its Tacticath force-sensing ablation catheter

GENEVA – June 13, 2012 - Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study.
12 Jun 2012

Endosense announces ce mark approval, first clinical use of the New tacticath® quartz force-sensing ablation catheter

GENEVA – June 12, 2012 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that its TactiCath Quartz force-sensing ablation catheter has been CE mark approved.
08 Jun 2012

TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect®

Leuven (BELGIUM) – June 8, 2012 – TiGenix (NYSE Euronext: TIG) announced today that its innovative cartilage repair therapy ChondroCelect® has obtained national reimbursement in the Netherlands.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка